[go: up one dir, main page]

RU2017114150A - COMBINED FACILITY FOR INJECTION - Google Patents

COMBINED FACILITY FOR INJECTION Download PDF

Info

Publication number
RU2017114150A
RU2017114150A RU2017114150A RU2017114150A RU2017114150A RU 2017114150 A RU2017114150 A RU 2017114150A RU 2017114150 A RU2017114150 A RU 2017114150A RU 2017114150 A RU2017114150 A RU 2017114150A RU 2017114150 A RU2017114150 A RU 2017114150A
Authority
RU
Russia
Prior art keywords
tool according
glucosamine
derivative
vitamin
sulfate
Prior art date
Application number
RU2017114150A
Other languages
Russian (ru)
Other versions
RU2017114150A3 (en
RU2737380C2 (en
Inventor
Алексей Валерьевич Чекалов
Original Assignee
Общество с ограниченной ответственностью "ФБК"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "ФБК" filed Critical Общество с ограниченной ответственностью "ФБК"
Priority to RU2017114150A priority Critical patent/RU2737380C2/en
Publication of RU2017114150A3 publication Critical patent/RU2017114150A3/ru
Publication of RU2017114150A publication Critical patent/RU2017114150A/en
Application granted granted Critical
Publication of RU2737380C2 publication Critical patent/RU2737380C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (39)

1. Средство для внутрисуставного введения, содержащее гиалуроновую кислоту или ее производное, глюкозамин или его производное, витамин С или его производное и соль цинка.1. The tool for intraarticular administration containing hyaluronic acid or its derivative, glucosamine or its derivative, vitamin C or its derivative and zinc salt. 2. Средство по п. 1, отличающееся тем, что производное гиалуроновой кислоты представляет собой гиалуронат натрия или сополимер гиалуроновой кислоты.2. The tool according to claim 1, characterized in that the derivative of hyaluronic acid is sodium hyaluronate or a copolymer of hyaluronic acid. 3. Средство по п. 1, отличающееся тем, что производное глюкозамина представляет собой соль глюкозамина.3. The tool according to p. 1, characterized in that the glucosamine derivative is a glucosamine salt. 4. Средство по п. 3, отличающееся тем, что соль глюкозамина представляет собой глюкозамина сульфат или глюкозамина гидрохлорид.4. The tool according to p. 3, characterized in that the glucosamine salt is glucosamine sulfate or glucosamine hydrochloride. 5. Средство по п. 1, отличающееся тем, что соль цинка представляет собой сульфат цинка.5. The tool according to p. 1, characterized in that the zinc salt is zinc sulfate. 6. Средство по п. 1, отличающееся тем, что представляет собой медицинское изделие для внутрисуставного введения.6. The tool according to p. 1, characterized in that it is a medical device for intraarticular administration. 7. Средство по п. 1, отличающееся тем, что представляет собой раствор для внутрисуставного введения.7. The tool according to p. 1, characterized in that it is a solution for intra-articular administration. 8. Средство по п. 1, отличающееся тем, что представляет собой гель для внутрисуставного введения.8. The tool according to p. 1, characterized in that it is a gel for intraarticular administration. 9. Средство по п. 1, отличающееся тем, что представляет собой имплантат для внутрисуставных инъекций.9. The tool according to p. 1, characterized in that it is an implant for intra-articular injection. 10. Средство по п. 1, отличающееся тем, что представляет собой заменитель или протез синовиальной жидкости.10. The tool according to p. 1, characterized in that it is a substitute or prosthesis for synovial fluid. 11. Средство по любому из пп. 6-10, отличающееся тем, что находится в предварительно заполненном шприце.11. The tool according to any one of paragraphs. 6-10, characterized in that it is in a pre-filled syringe. 12. Средство по п. 11, отличающееся тем, что объем указанного предварительно заполненного шприца составляет 2 или 3 мл.12. The tool according to claim 11, characterized in that the volume of said pre-filled syringe is 2 or 3 ml. 13. Средство по п. 1, отличающееся тем, что дополнительно содержит вспомогательные вещества.13. The tool according to p. 1, characterized in that it further comprises auxiliary substances. 14. Средство по п. 11, отличающееся тем, что вспомогательные вещества представляют собой воду для инъекций, и/или натрия хлорид, и/или фосфатный буфер.14. The tool according to p. 11, characterized in that the excipients are water for injection, and / or sodium chloride, and / or phosphate buffer. 15. Средство по п. 1, отличающееся тем, что содержит15. The tool according to p. 1, characterized in that it contains гиалуронат натрия от около 5 мг до около 40 мг на 1 мл,sodium hyaluronate from about 5 mg to about 40 mg per 1 ml, глюкозамина сульфат или глюкозамина гидрохлорид от около 5 мг до около 50 мг на 1 мл,glucosamine sulfate or glucosamine hydrochloride from about 5 mg to about 50 mg per 1 ml, витамин С от около 3 мг до около 50 мг на 1 мл,vitamin C from about 3 mg to about 50 mg per 1 ml, сульфат цинка от около 1 мг до около 5 мг на 1 мл.zinc sulfate from about 1 mg to about 5 mg per 1 ml. 16. Средство по п. 15, отличающееся тем, что содержит:16. The tool according to p. 15, characterized in that it contains: гиалуронат натрия около 15 мг/мл или около 20 мг/мл,sodium hyaluronate about 15 mg / ml or about 20 mg / ml, глюкозамина сульфат около 20 мг/мл или около 30 мг/мл,glucosamine sulfate about 20 mg / ml or about 30 mg / ml, витамин С около 10 мг/мл,vitamin C about 10 mg / ml, сульфат цинка около 5 мг/мл.zinc sulfate about 5 mg / ml. 17. Средство по п. 16, отличающееся тем, что содержит:17. The tool according to p. 16, characterized in that it contains: гиалуронат натрия 15 мг/мл или 20 мг/мл,sodium hyaluronate 15 mg / ml or 20 mg / ml, глюкозамина сульфат 20 мг/мл или 30 мг/мл,glucosamine sulfate 20 mg / ml or 30 mg / ml, витамин С 10 мг/мл,vitamin C 10 mg / ml, сульфат цинка 5 мг/мл.zinc sulfate 5 mg / ml. 18. Применение средства по любому из пп. 1-17 для лечения следующих заболеваний и состояний:18. The use of funds according to any one of paragraphs. 1-17 for the treatment of the following diseases and conditions: при лечении остеоартроза I-III стадии коленного, тазобедренного и других синовиальных суставов дегенеративно-дистрофического или травматического происхождения; in the treatment of osteoarthrosis of the I-III stage of the knee, hip and other synovial joints of degenerative-dystrophic or traumatic origin; при боли и ограничении подвижности, вызванных дегенеративно-дистрофическими или посттравматическими изменениями коленного, тазобедренного и других суставов; with pain and limitation of mobility caused by degenerative-dystrophic or post-traumatic changes in the knee, hip and other joints; в качестве вспомогательного средства при артроскопии и в ортопедической хирургии; as an aid in arthroscopy and in orthopedic surgery; при необходимости улучшения вязкоэластичных и защитных свойств синовиальной жидкости суставов; if necessary, improve the viscoelastic and protective properties of the synovial fluid of the joints; при дегенеративно-дистрофических состояний связочного аппарата, соединительнотканных и хрящевых структур; with degenerative-dystrophic conditions of the ligamentous apparatus, connective tissue and cartilage structures; при артрите в стадии ремиссии;with arthritis in remission; для профилактики дегенеративно-дистрофических заболеваний опорно-двигательного аппарата; for the prevention of degenerative diseases of the musculoskeletal system; в период реабилитации после перенесенных травм и оперативных вмешательств. during the rehabilitation period after injuries and surgical interventions. 19. Применение витамина С или его производного для изготовления средства для внутрисуставного введения по любому из пп. 1-17.19. The use of vitamin C or its derivative for the manufacture of funds for intra-articular administration according to any one of paragraphs. 1-17.
RU2017114150A 2017-04-24 2017-04-24 Combined agent for intraarticular administration RU2737380C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2017114150A RU2737380C2 (en) 2017-04-24 2017-04-24 Combined agent for intraarticular administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2017114150A RU2737380C2 (en) 2017-04-24 2017-04-24 Combined agent for intraarticular administration

Publications (3)

Publication Number Publication Date
RU2017114150A3 RU2017114150A3 (en) 2018-10-24
RU2017114150A true RU2017114150A (en) 2018-10-24
RU2737380C2 RU2737380C2 (en) 2020-11-27

Family

ID=63923061

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017114150A RU2737380C2 (en) 2017-04-24 2017-04-24 Combined agent for intraarticular administration

Country Status (1)

Country Link
RU (1) RU2737380C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109481398A (en) * 2018-12-18 2019-03-19 江西润泽药业有限公司 Aminoglucose injection and its preparation method and application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115944553B (en) * 2022-12-07 2024-12-31 华熙生物科技股份有限公司 Application of oligopeptides in improving the stability of cross-linked hyaluronic acid or its salts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
RU2468805C2 (en) * 2011-02-24 2012-12-10 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" Composition possessing analgesic, anti-inflammatory and locomotor function improving action
ITMI20131755A1 (en) * 2013-10-21 2015-04-22 Mero S R L BIORASSORIBLE COMPOSITION CONTAINING ANTIBACTERIAL AGENTS FOR THE TREATMENT OF LOMBAR PAIN

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109481398A (en) * 2018-12-18 2019-03-19 江西润泽药业有限公司 Aminoglucose injection and its preparation method and application

Also Published As

Publication number Publication date
RU2017114150A3 (en) 2018-10-24
RU2737380C2 (en) 2020-11-27

Similar Documents

Publication Publication Date Title
Karatosun et al. Intra-articular hyaluronic acid compared to exercise therapy in osteoarthritis of the ankle. A prospective randomized trial with long-term follow-up
Tang et al. Kinetics features changes before and after intra-articular hyaluronic acid injections in patients with knee osteoarthritis
CN1859918B (en) Application of hyaluronic acid in preparing medicine for treating acute and overstrain sprain and strain
RU2455028C1 (en) Method of treating osteoarthrosis of knee
JP2011037849A (en) Hyaluronic acid mixture used for treating and preventing peptic ulcer and duodenal ulcer
RU2017114150A (en) COMBINED FACILITY FOR INJECTION
KR20160002256A (en) Pharmaceutical composition for treating osteoarthritis comprising cross-linked hyaluronan as an active ingredient and method for treating osteoarthritis in a patient
US20160106774A1 (en) Liquid pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis
Hammuda et al. Use of ozone in temporomandibular joint arthrocentesis, clinical study
Fu et al. Intra-articular hyaluronic acid following knee immobilisation for 6 weeks in rabbits
US20240050628A1 (en) Injectable photocrosslinked hyaluronic acid hydrogels, production method thereof and their use for the treatment of osteoarthritis
JPH09176020A (en) Stable solution containing sodium hyaluronate
WO2023042120A1 (en) Composition comprising sodium hyaluronate and am inoacids for use in the orthopedic filed
RU2519119C1 (en) Method of treating degenerative and inflammatory-degenerative arthropathies
RU2008126108A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS CONTAINING CLODRONIC ACID AND HYALURONIC ACID
Saad Intra articular injection of hyaluronic acid alone in comparison with hyaluronic acid and PRP in the treatment of internal derangement of temporomandibular joint
RU2339331C1 (en) Repositioning device for treatment of intra-articular fractures of proximal part of shin bone
EA202191034A1 (en) CONJUGATES OF HYALURONIC ACID AND AMINO-BISPHOSPHONATES AND THEIR THERAPEUTIC APPLICATION
RU2732877C1 (en) Method for inducing focal osteoarthrosis in distal epiphysial cartilage of femur in sheep
Ishaq et al. RADIOGRAPHIC COMPARATIVE REGENERATIVE EFFECTS OF HYALURONATE AND PIROXICAM IN OSTEOARTHRITIS MODELS OF RATS
건우이 et al. Hyaluronic Acid and Platelet-Rich Plasma Injections in Foot and Ankle Disorders
Elzohry Updates in Knee Joint Osteoarthritis
WO2017025903A1 (en) Injectable liquid composition for use in the intra-articular infiltration therapy
RU2648641C2 (en) Biologically active additive to the food of chondroprotective action
Gunaki et al. Study of outcome of knee joint in patients with fracture distal femur versus fracture ipsilateral femur and tibia

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20190312

HE9A Changing address for correspondence with an applicant
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190730

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20200903